Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 29-32

  Batel Copel, L M ^a,b   Kornblith, A B ^a   Batel, P C ^a   Holland, J C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUT CURIE   (France)

Author keywords

cancer; clinical trials; performance status; quality of life

Indexed keywords

CANCER THERAPY; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; KARNOFSKY PERFORMANCE STATUS; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0031018391     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00414-5     Document Type: Review

References (23)

1. 1. Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
2. 2. Shipper H, Clinch J, McMurray A, Lewitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984, 2, 472-482.
3. 3. Karnovsky DA, Buchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In CM M, ed. Evaluation of Chemotherapeutic Agents. New York, Columbia University Press, 1949, 199-205.
4. 4. Zubrod CG, Schneiderman M, Fre E, et al. Appraisal of methods for the study of chemotherapy in cancer in man: comparative therapeutic trial of nitrogen mustard triethylene triphosphate. J Chronic Dis 1960, 11, 7-33.
5. 5. Conill CD, Verger MD, Salomero M. Performance status assessment in cancer patients. Cancer 1990, 65, 1864-1866.
6. 6. Willemse P, Van Lithe P, Mulder N, et al. Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer 1990, 26, 345-352.
7. 7. Hill M, Norman A, Cunningham D, et al. Impact of protracted venous infusion of fluorouracil with or without interferon alpha 2b on tumor response, survival, and Quality of Life in advanced colorectal cancer. J Clin Oncol 1995, 13, 2317-2323.
8. 8. Cunningham D, Zalcberg J, Rath U, et al. Tomudex: results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995, 31A, 1945-1954.
9. 9. Sundareson N, Sachdev VP, Holland J, et al. Surgical treatment of spinal cord compression from epidural metastasis. J Clin Oncol 1995, 13, 2330-2335.
10. 10. Ludwig H, Sundal E, Pecherstofer R, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995, 75, 2319-2329.
11. 11. Clavel M, Bonneterre J, D'Hallens J, Paillarse J. Oral odansetron in the prevention of chemotherapy induced emesis in breast cancer patients. Eur J Cancer 1995, 31A, 15-19.
12. 12. Lazlo J, Clark R, Hanson D, Tyson L, Grumpler L, Galla R. Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic and anxiolytic effects. J Clin Oncol 1985, 3, 864-869.
13. 13. Bjermer L, Gruber A, Sue-Chu M, Sandström T, Eksborg S, Henriksson R. Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion. A randomized study. Eur J Cancer 1995, 31A, 2203-2208.
14. 14. Jones S, Winer S, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracyclines refractory advanced breast cancer. J Clin Oncol 1995, 13, 2567-2574.
15. 15. North C, North R, Epstein J, Piandosi S, Wharam M. Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 1990, 66, 6-14.
16. 16. Bruera E, MacMillan K, Kuehn X, Hanson J, MacDonald N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990, 66, 1279-1282.
17. 17. Robertson AG, Reeo NS, Raltson AH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo controlled study. J Clin Oncol 1995, 13, 2427-2430.
18. 18. Hayes D, Van Zyle JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in post menopausal patients with metastatic breast cancer. J Clin Oncol 1995, 13, 2556-2566.
19. 19. Gill TM, Feinstein AR. A critical appraisal of the quality of life measurements. J Am Med Assoc 1994, 8, 364-368.
20. 20. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994, 12, 608-616.
21. 21. Coscarelli Shag C, Heinrich RL, Ganz P. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984, 2, 187-193.
22. 22. Yates J, Chalmers B, McKegney P. Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 1980, 45, 2220-2224.
23. 23. Wilson B, Cleary P. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. J Am Med Assoc 1995, 273, 59-65.